| |
H1N1 positives
|
Corona positives
|
HCB
|
HCC
|
|---|
| |
A
|
B
|
C
|
AB1
|
AC1
|
A
|
B
|
C
|
AB1
|
AC1
|
p
|
|---|
| |
SRH (mm2), geometric mean
|
p-value
|
SRH (mm2), geometric mean
|
p-value
| |
|---|
|
A/H1N1/California
|
16.1
|
46.9
|
30.6
|
<0.001
|
0.003
|
21.1
|
29.8
|
24.3
|
0.2
|
0.4
|
<0.001
|
0.001
|
| |
IFN-γ (pg/mL)
|
|
A/H1N1/Brisbane
|
90
|
460
|
274
|
<0.001
|
0.01
|
156
|
227
|
159
|
0.6
|
0.2
|
<0.001
|
0.01
|
|
A/H1N1/Solomon
|
104
|
416
|
272
|
<0.001
|
0.01
|
124
|
212
|
159
|
0.2
|
0.2
|
<0.01
|
0.03
|
|
A/H3N2/Uruguay
|
125
|
420
|
292
|
<0.001
|
0.09
|
222
|
224
|
244
|
0.8
|
0.4
|
<0.001
|
0.09
|
|
A/H3N2/Wisconsin
|
137
|
408
|
298
|
<0.001
|
0.02
|
212
|
236
|
242
|
0.5
|
0.4
|
0.001
|
0.04
|
|
A/H5N1/Vietnam
|
316
|
546
|
392
|
<0.01
|
0.3
|
355
|
394
|
367
|
0.7
|
0.8
|
<0.01
|
0.3
|
|
B/Florida
|
218
|
307
|
327
|
0.24
|
0.2
|
216
|
370
|
240
|
0.08
|
0.7
|
0.4
|
0.1
|
|
B/Malaysia
|
173
|
260
|
251
|
0.06
|
0.25
|
160
|
249
|
177
|
0.2
|
0.5
|
0.7
|
0.11
|
|
M1
|
34
|
127
|
48
|
<0.01
|
0.08
|
18
|
24
|
25
|
0.04
|
0.15
|
0.07
|
0.25
|
|
M2
|
19
|
18
|
19
|
0.3
|
0.9
|
18
|
18
|
18
|
0.9
|
0.9
|
0.4
|
0.9
|
|
CFP-10
|
19
|
25
|
18
|
0.9
|
0.3
|
18
|
18
|
18
|
0.6
|
0.3
|
0.9
|
0.7
|
|
PHA
|
502
|
535
|
588
|
0.9
|
0.08
|
524
|
589
|
544
|
0.1
|
0.5
|
0.2
|
0.25
|
|
Mean IFN-γ diff.
|
148
|
265
|
233
| | |
173
|
220
|
189
| | | | |
|
N
|
21
|
21
|
21
| | |
38
|
15
|
38
| | | | |
- The Wilcoxon-Mann–Whitney rank-sum test was used to calculate the p-values. AB1: difference between time point A and B; AC1: difference between time point A and C; HCB: difference between pdmH1N1 positive and coronavirus positive at time point B. HCC difference between pdmH1N1 positive and coronavirus positive at time point C. Note the strong immune responses at time point B in participants with pdmH1N1 infection; this response was reduced at the end of the study (time point C). P values below 0.05 are indicated in bold.
